- Home
- RDCM vs CRBP Comparison
RDCM vs CRBP Comparison
Compare RDCM & CRBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RDCM
- CRBP
- Stock Information
- Founded
- RDCM 1985
- CRBP 2009
- Country
- RDCM Israel
- CRBP United States
- Employees
- RDCM N/A
- CRBP N/A
- Industry
- RDCM Computer peripheral equipment
- CRBP Biotechnology: Pharmaceutical Preparations
- Sector
- RDCM Technology
- CRBP Health Care
- Exchange
- RDCM Nasdaq
- CRBP Nasdaq
- Market Cap
- RDCM 157.9M
- CRBP 143.7M
- IPO Year
- RDCM 1997
- CRBP N/A
- Fundamental
- Price
- RDCM $14.08
- CRBP $11.96
- Analyst Decision
- RDCM Strong Buy
- CRBP Strong Buy
- Analyst Count
- RDCM 2
- CRBP 8
- Target Price
- RDCM $15.00
- CRBP $62.00
- AVG Volume (30 Days)
- RDCM 71.7K
- CRBP 256.8K
- Earning Date
- RDCM 02-12-2025
- CRBP 03-11-2025
- Dividend Yield
- RDCM N/A
- CRBP N/A
- EPS Growth
- RDCM 660.55
- CRBP N/A
- EPS
- RDCM 0.46
- CRBP N/A
- Revenue
- RDCM $58,755,000.00
- CRBP N/A
- Revenue This Year
- RDCM $18.92
- CRBP N/A
- Revenue Next Year
- RDCM $11.27
- CRBP N/A
- P/E Ratio
- RDCM $30.30
- CRBP N/A
- Revenue Growth
- RDCM 17.80
- CRBP N/A
- 52 Week Low
- RDCM $8.18
- CRBP $6.63
- 52 Week High
- RDCM $14.33
- CRBP $61.90
- Technical
- Relative Strength Index (RSI)
- RDCM 67.92
- CRBP 46.35
- Support Level
- RDCM $11.90
- CRBP $11.02
- Resistance Level
- RDCM $13.37
- CRBP $13.28
- Average True Range (ATR)
- RDCM 0.77
- CRBP 0.67
- MACD
- RDCM 0.19
- CRBP 0.24
- Stochastic Oscillator
- RDCM 90.83
- CRBP 87.07
About RDCM Radcom Ltd.
Radcom Ltd Ltd is engaged in providing network intelligence, 5G ready cloud-native, network intelligence solutions for telecom operators transitioning to 5G. The company has a network intelligence solution for 5G namely Radcom ACE. Its products consist of Radcom Network Visibility, Radcom Service Assurance, and Radcom Network Insights. It has offices in Israel, the United States, Brazil, and India. Key revenue is derived from sales in North America.
About CRBP Corbus Pharmaceuticals Holdings Inc.
Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.